article thumbnail

COVID prompts another milestone, as India clears first DNA vaccine

pharmaphorum

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98
article thumbnail

Accelerating recombinant protein vaccine discovery

Drug Discovery World

While a typical chemisty, manufacturing and controls (CMC) timeline from DNA to Investigational New Drug (IND) application in 2015 would have been approximately 24 months, by 2023 the same pathway was expected to take only 10 months. In particular, we must work to accelerate recombinant protein vaccine development.

Protein 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Issues Two Guidance Documents on Food Allergen Labeling Requirements

FDA Law Blog

labeling of major food allergens in bulk foods, dietary supplements, protein-free ingredients, and foods produced through genetic engineering); and. 1, 2023; The applicability of food allergen labeling requirements to specific products (e.g., Other technical labeling matters. 1, 2023, sesame.

article thumbnail

Q&A with Mark Garner: The golden age of cancer research  

Drug Discovery World

For example, in CAR-T-cell therapy, scientists can take T-cells from a patient and ex vivo (outside the body) genetically engineer them to effectively target and kill cancerous cells, then infuse them back in to the patient. Of course, if a patient’s tumour does not have this protein, then this type of treatment won’t be effective.

article thumbnail

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.

Gene 262
article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

article thumbnail

Global advances in synthetic biology

Drug Discovery World

The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. Lu Rahman selects some recent synthetic biology innovations and the potential they hold to benefit drug discovery. .